This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Innate Pharma. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Hatem Abdelazim: Innovator in Cancer Treatment
Introduction
Hatem Abdelazim is a notable inventor based in Marseilles, France. He has made significant contributions to the field of oncology, particularly in the treatment of T cell lymphomas. His innovative approach combines specific compounds with established chemotherapeutic agents to enhance treatment efficacy.
Latest Patents
Hatem Abdelazim holds a patent for the treatment of T cell lymphoma. The patent details methods for treating T cell lymphomas using compounds that specifically bind KIR3DL2 in combination with chemotherapeutic agents, notably gemcitabine and/or oxaliplatin. This treatment is particularly beneficial for patients with peripheral T cell lymphomas, such as PTCL-NOS. He has 1 patent to his name.
Career Highlights
Hatem Abdelazim is currently associated with Innate Pharma, a company dedicated to developing innovative immunotherapies for cancer treatment. His work focuses on advancing therapeutic options for patients suffering from challenging forms of cancer.
Collaborations
Hatem collaborates with Carine Paturel, contributing to the development of novel treatment strategies in oncology.
Conclusion
Hatem Abdelazim's work in cancer treatment exemplifies the impact of innovative thinking in medicine. His contributions are paving the way for more effective therapies for T cell lymphomas, ultimately improving patient outcomes.